Response assessment of bevacizumab in patients with recurrent malignant glioma using [18F]Fluoroethyl-l-tyrosine PET in comparison to MRI

[1]  G. Fink,et al.  Assessment of Treatment Response in Patients with Glioblastoma Using O-(2-18F-Fluoroethyl)-l-Tyrosine PET in Comparison to MRI , 2012, The Journal of Nuclear Medicine.

[2]  Tracy T Batchelor,et al.  Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. , 2012, Cancer research.

[3]  Ronald Boellaard,et al.  Mutatis Mutandis: Harmonize the Standard! , 2012, The Journal of Nuclear Medicine.

[4]  R. Baum,et al.  Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine (F-18 FET) PET for Glioma Grading: Assessment of Individual Probability of Malignancy , 2011, Clinical nuclear medicine.

[5]  Y. Kienast,et al.  Bevacizumab Has Differential and Dose-Dependent Effects on Glioma Blood Vessels and Tumor Cells , 2011, Clinical Cancer Research.

[6]  H. Kostron,et al.  O-(2-18F-Fluoroethyl)-L-Tyrosine PET Predicts Failure of Antiangiogenic Treatment in Patients with Recurrent High-Grade Glioma , 2011, The Journal of Nuclear Medicine.

[7]  Gabriele Stoffels,et al.  Prognostic value of early [18F]fluoroethyltyrosine positron emission tomography after radiochemotherapy in glioblastoma multiforme. , 2011, International journal of radiation oncology, biology, physics.

[8]  Michael Sabel,et al.  Comparison of 18F-FET PET and 5-ALA fluorescence in cerebral gliomas , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[9]  A. von Deimling,et al.  Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas. , 2011, Neuro-oncology.

[10]  M. Weller,et al.  Patterns of Progression in Malignant Glioma Following Anti-VEGF Therapy: Perceptions and Evidence , 2011, Current neurology and neuroscience reports.

[11]  R. Jain,et al.  Polarization of tumor-associated macrophages: a novel strategy for vascular normalization and antitumor immunity. , 2011, Cancer cell.

[12]  Jonathan R. Young,et al.  Advances in MRI Assessment of Gliomas and Response to Anti-VEGF Therapy , 2011, Current neurology and neuroscience reports.

[13]  Susan M. Chang,et al.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  C. Kramm,et al.  Intensive chemotherapy improves survival in pediatric high‐grade glioma after gross total resection: results of the HIT‐GBM‐C protocol , 2010, Cancer.

[15]  W. Heiss,et al.  Patient-Tailored, Imaging-Guided, Long-Term Temozolomide Chemotherapy in Patients with Glioblastoma , 2010, Molecular imaging.

[16]  Gereon R. Fink,et al.  Volumetry of [11C]-methionine PET uptake and MRI contrast enhancement in patients with recurrent glioblastoma multiforme , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[17]  M. Weller,et al.  Rechallenge with temozolomide in patients with recurrent gliomas , 2009, Journal of Neurology.

[18]  Jochen Herms,et al.  Long-sustaining response in a patient with non-resectable, distant recurrence of glioblastoma multiforme treated by interstitial photodynamic therapy using 5-ALA: case report , 2008, Journal of Neuro-Oncology.

[19]  John Sampson,et al.  Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Jochen Herms,et al.  FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[21]  C. Götz,et al.  Serial O-(2-[18F]fluoroethyl)-L-tyrosine PET for monitoring the effects of intracavitary radioimmunotherapy in patients with malignant glioma , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[22]  W. Koch,et al.  Analysis of 18F-FET PET for grading of recurrent gliomas: is evaluation of uptake kinetics superior to standard methods? , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[23]  Karl Herholz,et al.  Use of 11C-methionine PET to monitor the effects of temozolomide chemotherapy in malignant gliomas , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[24]  R. Goldbrunner,et al.  O-(2-[18F]fluoroethyl)-l-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[25]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[26]  Karl-Josef Langen,et al.  O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. , 2005, Brain : a journal of neurology.

[27]  K. Hamacher,et al.  O-(2-[18F]fluorethyl)-L-tyrosine PET in the clinical evaluation of primary brain tumours , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[28]  B. Radotra,et al.  Quantitation of angiogenesis and its correlation with vascular endothelial growth factor expression in astrocytic tumors. , 2004, Analytical and quantitative cytology and histology.

[29]  J. Dichgans,et al.  One week on/one week off: A novel active regimen of temozolomide for recurrent glioblastoma , 2004, Neurology.

[30]  Rakesh K Jain,et al.  Molecular regulation of vessel maturation , 2003, Nature Medicine.

[31]  K. Hamacher,et al.  Efficient routine production of the 18F-labelled amino acid O-2-18F fluoroethyl-L-tyrosine. , 2002, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[32]  P. Carmeliet,et al.  Angiogenesis in cancer and other diseases , 2000, Nature.

[33]  M. Schwaiger,et al.  Investigation of transport mechanism and uptake kinetics of O-(2-[18F]fluoroethyl)-L-tyrosine in vitro and in vivo. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[34]  R. Blasberg,et al.  “Facilitated” Amino Acid Transport is Upregulated in Brain Tumors , 1998, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[35]  S. Piantadosi,et al.  Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas , 1995, The Lancet.

[36]  T. Cascino,et al.  Response criteria for phase II studies of supratentorial malignant glioma. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  Karl Herholz,et al.  Integration of Functional Data (PET) into Brain Surgery Planning and Neuronavigation , 2007 .

[38]  J. Schnabel,et al.  Image Registration of Structural and Physiological MR Images of Abnormal Anatomy , 2007 .

[39]  S. Piantadosi,et al.  Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. , 1995, Lancet.